tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
ACRS Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsACRS Upcoming Earnings Report: What to Expect?
2M ago
Aclaris Therapeutics’ ATI-045 Study: A Potential Game-Changer for Atopic Dermatitis
Premium
Company Announcements
Aclaris Therapeutics’ ATI-045 Study: A Potential Game-Changer for Atopic Dermatitis
2M ago
Aclaris Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating
Premium
Ratings
Aclaris Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating
2M ago
Aclaris Therapeutics reports Q2 EPS (13c), consensus (13c)
PremiumThe FlyAclaris Therapeutics reports Q2 EPS (13c), consensus (13c)
5M ago
Positive Outlook for Aclaris Therapeutics Driven by Promising Trial Results and Pipeline Advancements
Premium
Ratings
Positive Outlook for Aclaris Therapeutics Driven by Promising Trial Results and Pipeline Advancements
5M ago
Closing Bell Movers: Qorvo, Starbucks jump after quarterly reports
Premium
The Fly
Closing Bell Movers: Qorvo, Starbucks jump after quarterly reports
5M ago
Aclaris Therapeutics Highlights Clinical Pipeline and Outlook
PremiumCompany AnnouncementsAclaris Therapeutics Highlights Clinical Pipeline and Outlook
6M ago
Aclaris Therapeutics: Promising Pipeline and Strategic Trials Justify Buy Rating
Premium
Ratings
Aclaris Therapeutics: Promising Pipeline and Strategic Trials Justify Buy Rating
6M ago
Aclaris Therapeutics initiates Phase 1a/1b program for ATI-052
Premium
The Fly
Aclaris Therapeutics initiates Phase 1a/1b program for ATI-052
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100